title: Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma.
abstract: OBJECTIVE
  Therapy of colorectal tumors (CRC) based on histology and clinical factors is insufficient to predict the evolution of each patient. The finding of molecular abnormalities able to differentiate subgroups of patients with bad prognosis will improve our ability to treat them successfully. Our purpose was to analyze retrospectively the prognostic input of E-cadherin, beta-catenin, metalloproteinases (MMPs) (7 and 9), and tissue inhibitors of metalloproteinases (TIMPs) (1 and 2) in patients with a follow-up period of 5 years.
  
  
  METHODS
  Antigen expression was analyzed by immunohistochemistry. Prognostic evaluation was performed with the multivariate proportional hazards model.
  
  
  RESULTS
  We demonstrated a concomitant loss of E-cadherin and beta-catenin at membranous level and an abnormal accumulation of nuclear beta-catenin. Besides, we found that all MMPs and TIMPs studied were overexpressed in CRC tissue. There was no association between the expression of any of these molecules and the known clinical-pathological parameters employed in CRC pathology. A multivariate analysis demonstrated that the overall survival could be independently predicted by the loss of E-cadherin and the overexpression of TIMP-2.
  
  
  CONCLUSIONS
  The expression of E-cadherin and TIMP-2 could be relevant in determining the prognosis of CRC patients and providing a more accurate mechanism for their classification.
authors.affiliation: Research Area of the Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Roca
authors.forename: Laura V
authors.initials: LV
authors.lastname: Mauro
authors.forename: Ana
authors.initials: A
authors.lastname: Morandi
authors.forename: Fernando
authors.initials: F
authors.lastname: Bonadeo
authors.forename: Carlos
authors.initials: C
authors.lastname: Vaccaro
authors.forename: Guillermo Ojea
authors.initials: GO
authors.lastname: Quintana
authors.forename: Sergio
authors.initials: S
authors.lastname: Specterman
authors.forename: Elisa Bal
authors.initials: EB
authors.lastname: de Kier Joffé
authors.forename: María Guadalupe
authors.initials: MG
authors.lastname: Pallotta
authors.forename: Lydia Inés
authors.initials: LI
authors.lastname: Puricelli
authors.forename: José
authors.initials: J
authors.lastname: Lastiri
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D015820:Cadherins / Q000096:biosynthesis*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D020782:Matrix Metalloproteinases / Q000096:biosynthesis*; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000096:biosynthesis; D019714:Tissue Inhibitor of Metalloproteinases / Q000096:biosynthesis*; D051176:beta Catenin / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D019715:Tissue Inhibitor of Metalloproteinase-1; D019714:Tissue Inhibitor of Metalloproteinases; D051176:beta Catenin; D019716:Tissue Inhibitor of Metalloproteinase-2; D020782:Matrix Metalloproteinases